IO Biotech reports ~$142M cash as of Dec 31, 2022; runway through Q3 2024

IO Biotech, Inc.

Preliminary cash and cash equivalents of ~$142M as of Dec 31, 2022 (subject to audit).
Cash runway projected through Q3 2024, per updated corporate presentation.
Updated presentation to be used at Oppenheimer 33rd Annual Healthcare Conference on Mar 14, 2023.
No other financial results or guidance changes disclosed; preliminary cash is unaudited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.